Compare Ascendis Pharma A/S (ASND) vs SiTime Corporation (SITM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs SiTime Corporation — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while SiTime Corporation trades at $619.94 (market cap $18.83B). The key difference: Ascendis Pharma A/S and SiTime Corporation are close in size by market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, SiTime Corporation nearer its low. Which is the better fit depends on your goals.
| ASND | SITM | |
|---|---|---|
Market Cap | $17.74B | $18.83B |
Sector | Health | Technology |
52-Week High | $277.18 | $901.60 |
52-Week Low | $163.32 | $190.16 |
Enterprise Value | $18.11B | $18.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
SITM trades at $628.94, down 2.96% on the day, with a bearish technical signal from moving averages. The company shows strong revenue growth and consistent earnings beats, with Q1 2026 EPS of $1.44 surpassing estimates. Recent acquisition of Renesas' timing business and raised AI-driven growth guidance highlight strategic expansion. However, negative net income margins and high P/S ratio of 42.42 indicate valuation concerns amid profitability challenges.
Outlook remains positive with 100% analyst buy ratings and a $743.75 consensus target, suggesting 18% upside. Key risks include sustained unprofitability, integration execution from acquisitions, and market volatility. The stock's trajectory hinges on achieving projected 2026 profitability improvements and capitalizing on AI infrastructure demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
